Press releases and Tweets by @cellcentric
CellCentric at AACR 2018: first-in-class p300/CBP inhibitor drug candidate, for prostate cancer and beyond
Posted on April 17th 2018
CellCentric’s oral drug candidate CCS1477 addresses the large and growing population of late stage prostate cancer patients who have inherent or acquired resistance to current second-line anti-androgen therapies. It can be used after or in combination with abiraterone (Zytiga), enzalutamide (Xtandi) and apalutamide (Erleada). New pre-clinical data is presented today at the annual American Association of Cancer Research (AACR) meeting, Chicago, supporting its targeted use not just for prostate cancer (CRPC), but also for other indications including certain haematological cancers (AML and multiple myeloma).
CellCentric’s first-in-class p300/CBP inhibitor drug CCS1477; capsule production complete ready for the clinic
Posted on March 7th 2018
Production of CCS1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical trials to investigate the novel drug’s tolerability and efficacy in treating late stage prostate cancer (CRPC). The active component is a p300/CBP bromodomain inhibitor that has a profound effect on the drivers of CPRC. It addresses the resistance seen in tumours treated with current second generation anti-hormonal drugs. Formulation and GMP manufacture of the capsules was carried out by Quay Pharma.
Posted on January 31st 2018
CellCentric and The Institute of Cancer Research, London, have signed a research agreement to further explore the effects of CellCentric’s drug candidate CCS1477 on prostate cancer. In addition, Karen Knudsen, Johann de Bono and Myles Brown have been granted a Prostate Cancer Foundation challenge award of $1m to investigate the molecular and biological effects of CCS1477 in the context of clinical impact.
Posted on December 4th 2017
CellCentric today presents its latest pre-clinical efficacy data on drug Candidate CCS1477, at the AACR’s Annual Prostate Cancer meeting, Orlando. This novel inhibitor which targets the bromodomain of p300/CBP, is advancing to the clinic early 2018. Latest results continue to support CCS1477’s anti-cancer efficacy, as well as its clear differentiation versus other epigenetic-related inhibitors targeting bromodomains (BET inhibitors), such as JQ-1, iBET-151 and OTX-015.
Posted on October 5th 2017
CellCentric presents new data on drug Candidate CCS1477 and its relevance to the aggressive, castrate-resistant form of prostate cancer, at the 24th Annual Prostate Cancer Foundation Scientific Retreat. The PCF meeting is the foremost scientific conference on the biology and treatment of prostate cancer. This is a closed, invitation only event which brings together the best researchers, physicians and medical oncologists from academia, non-profit organisations and industry.
Posted on September 5th 2017
CellCentric has signed an agreement with Laura Pasqualucci, Professor of Pathology and Cell Biology at Columbia University Medical School, New York USA, to explore the relevance of the company’s drug Candidate, CCS1477, in treating certain haematological cancers. This is in addition to existing collaborations with Professor Tim Somervaille, Consultant Haematologist and Senior Group Leader at the Cancer Research UK Manchester Institute and Professor Brian Huntly, Consultant Haematologist and Professor of Leukaemia Stem Cell Biology at the Cambridge Stem Cell Institute.
Posted on June 3rd 2017
CellCentric’s oral drug candidate CCS1477 targets p300/CBP for the treatment of castrate resistant prostate cancer (CRPC), the lethal form of the disease. Further biomarker and efficacy data is presented today supporting its application both as a monotherapy and in combination with other drugs such as Enzalutamide. CellCentric is taking CCS1477 into the clinic in the UK and US, with Johann de Bono as the lead clinical Principal Investigator, a renowned world leader in the development of novel treatments for prostate cancer.
Posted on April 3rd 2017
CellCentric’s cancer drug candidate CCS1477 is initially targeted for the treatment of castrate resistant prostate cancer (CRPC). Further supporting data is presented today at the 2017 annual meeting of the American Association for Cancer Research (AACR) in Washington, DC. CCS1477 can also be used against tumours that harbour p300 or CBP mutations, opening up application areas including bladder, lung and haematological cancers.
Posted on February 16th 2017
CellCentric has developed a potent, selective, orally bioavailable small molecule inhibitor of p300/CBP. These targets are key regulators of cancer cells, and specifically play a critical role in the progression of the aggressive form of prostate cancer. Key pre-clinical efficacy data on CellCentric’s compound CCS1477 is presented today at GU-ASCO, Orlando (1).
Posted on November 8th 2016
CellCentric is developing first in class drug compounds against a key regulator of cancer. P300/CBP are twin (paralogue) histone acetyltransferase proteins, that act as transcriptional co-factors. When inhibited they cause the down regulation of the androgen receptor (AR) and its variants. It also decreases c-Myc, another key cancer driver.
Posted on February 9th 2016
CellCentric is developing proprietary anti-cancer compounds that target androgen receptor (AR) regulation. These hold promise for castrate resistant prostate cancer (CRPC) as well as other cancers. As the company moves towards Candidate selection and IND qualification, CellCentric is expanding its team for future activities.
Posted on October 20th 2015
Further investment from Morningside Venture Investments Ltd and Providence Investment Company Ltd will see the company take its small molecule drug discovery programme for the most aggressive form of prostate cancer (CRPC) through candidate finalisation and IND-enabling studies. CellCentric’s proprietary compounds target a histone acetyl transferase (HAT) that is key in androgen receptor regulation.
Posted on October 15th 2015
CellCentric is developing small molecule inhibitors for the most aggressive form of prostate cancer (CRPC). In March 2013, the company secured support from InnovateUK, combined with venture capital investment, to develop novel small molecule modulators of the androgen receptor pathway. This programme has now completed, on time and on budget.
Posted on May 20th 2014
A European patent award has now been received, in addition to recent US grants, that covers a technology for site specific gene demethylation. This technology can be a useful tool in understanding the epigenetic regulation of cells, and the mechanisms used to control cell fate. This has implications for understanding disease processes and potentially the development of new treatments.
Posted on June 25th 2013
New investment coupled with a major award from the UK’s innovation agency, the Technology Strategy Board, will provide funding for over two years to conduct lead optimisation and clinical candidate generation on inhibitors against a specific deubiquitinase target, demonstrated to play a key role in the progression of prostate cancer.
Posted on March 16th 2013
New investment fuels further lead optimisation work on inhibitors against a specific deubiquitinase target. Compounds generated to date effect both native and splice variant androgen receptors, which are key in the progression of the most lethal form of prostate cancer. They offer a clear opportunity to address resistance mechanisms seen with current agents for the disease.
CellCentric and ZoBio enter into partnership to develop lead compounds against epigenetic drug targets
Posted on June 20th 2012
CellCentric and ZoBio are pleased to announce that the companies are working together to discover lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets. ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric. Hit to lead and lead optimisation activities will be further supported by ZoBio’s biophysical and medicinal chemistry research services.
Posted on December 8th 2011
CellCentric joins a group of leading academic researchers around the world to investigate epigenetic mechanisms underlying diabetes. CellCentric is the sole commercial partner to a new consortium being funded by the European Union. The collaboration may yield new targets for small molecule therapeutics.
Posted on April 5th 2011
The Minister for Universities and Science, David Willetts, has appointed three new members to the Council of the Biotechnology and Biological Sciences Research Council (BBSRC)
Posted on March 14th 2011
New funding sees CellCentric expand drug discovery activities across multiple epigenetic targets.
Posted on December 9th 2010
A new review of second generation epigenetic targets highlights CellCentric as a key leader in a field which is becoming a strategic research and development imperative for many pharmaceutical companies.
Posted on November 18th 2010
CellCentric's Scientific Director Nessa Carey and Programme Manager Jonathan Best publish a review on epigenetics and non-oncology therapeutic indications in Drug Discovery Today.
Posted on August 31st 2010
Prof Azim Surani FRS CBE has been awarded the Royal Society’s Royal Medal for his pivotal contributions to the understanding of early mammalian development.
Posted on May 24th 2010
Professor Wolf Reik Head of the Laboratory of Developmental Genetics and Imprinting at the Babraham Institute has been elected to the Fellowship of the Royal Society. Professor Reik is a world leading authority in the field of epigenetics.
Posted on May 11th 2010
Grant funding has been gained from the Biotechnology and Biological Sciences Research Council (BBSRC) to further CellCentric’s investigation of epigenetic control mechanisms and the identification of small molecule modulators, in collaboration with Professor Wolf Reik at the Babraham Institute.
Posted on February 23rd 2010
From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.
CellCentric heads new collaboration with Sigma-Aldrich, The Automation Partnership and leading epigenetic researchers
Posted on February 16th 2010
The University of Cambridge, UCL (University College London), CellCentric, Sigma-Aldrich and The Automation Partnership embark on a collaboration to define markers of epigenetic reprogramming, supported by £1.1m from the UK Government’s Technology Strategy Board.
Posted on January 25th 2010
New data from Prof. Wolf Reik of the Babraham Institute, Cambridge, highlights the key role of the cytidine deaminase AID in DNA demethylation and the reprogramming of cells.
Posted on January 6th 2010
CellCentric's Director of Exploratory Research, Nessa Carey and colleague Jonathan Best publish a review on epigenetics and oncology in Drug Discovery Today.